Bruceantin
Based on 2 publication(s) in Google Scholar
Bruceantin ((-)-Bruceantin) is a quassinoid found in B. javanica. Bruceantin activates caspase signaling pathway, causes the mitochondrial dysfunction, inhibits cell proliferation, induces cell differentiation and apoptosis. Bruceantin exhibits anti-leukemia and antiprotozoal activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.67%
- No. CAS: 41451-75-6
- Fòrmula: C28H36O11
- Peso molecular:548.58
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Bruceantin
MoreVer todos los productos específicos de isoformas Caspase
MoreVer todos los productos específicos de isoformas Parasite
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BV-173 | IC50 |
<15 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human BV173 cells by trypan blue exclusion method
Cytotoxicity against human BV173 cells by trypan blue exclusion method
|
[PMID: 14987068] |
| Daudi | IC50 |
<15 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human Daudi cells by trypan blue exclusion method
Cytotoxicity against human Daudi cells by trypan blue exclusion method
|
[PMID: 14987068] |
| HeLa | IC50 |
0.029 μM
Compound: 9; BRC
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 33289552] |
| HeLa | IC50 |
0.051 μM
Compound: 7
|
Inhibition of protein synthesis in human HeLa cells assessed as [35S]methionine incorporation into protein treated for 45 mins before [35S]methionine addition by Whatman paper analysis
Inhibition of protein synthesis in human HeLa cells assessed as [35S]methionine incorporation into protein treated for 45 mins before [35S]methionine addition by Whatman paper analysis
|
[PMID: 19199792] |
| HL-60 | EC50 |
0.02 μM
Compound: 2
|
Induction of cell differentiation in human HL60 cells assessed as superoxide anion production after 4 days by NBT reduction assay
Induction of cell differentiation in human HL60 cells assessed as superoxide anion production after 4 days by NBT reduction assay
|
[PMID: 11754601] |
| HL-60 | IC50 |
0.04 μM
Compound: 2
|
Antiproliferative activity against human HL60 cells assessed as inhibition of [3H]thymidine incorporation after 4 days by liquid scintillation counter
Antiproliferative activity against human HL60 cells assessed as inhibition of [3H]thymidine incorporation after 4 days by liquid scintillation counter
|
[PMID: 11754601] |
| HL-60 | IC50 |
0.04 μM
Compound: 2
|
Cytotoxicity against human HL60 cells assessed as loss of membrane integrity after 4 days by trypan blue exclusion assay
Cytotoxicity against human HL60 cells assessed as loss of membrane integrity after 4 days by trypan blue exclusion assay
|
[PMID: 11754601] |
| HL-60 | IC50 |
12.2 nM
Compound: Bruceantin
|
Induction of apoptosis in human HL60 cells after 24 hrs by DAPI staining
Induction of apoptosis in human HL60 cells after 24 hrs by DAPI staining
|
[PMID: 14987068] |
| HL-60 | IC50 |
20 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human HL60 cells by trypan blue exclusion method
Cytotoxicity against human HL60 cells by trypan blue exclusion method
|
[PMID: 14987068] |
| HT-29 | IC50 |
0.022 μM
Compound: 9; BRC
|
Antiproliferative activity against human HT-29 cells
Antiproliferative activity against human HT-29 cells
|
[PMID: 33289552] |
| Kasumi 1 | IC50 |
20 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human Kasumi-1 cells by trypan blue exclusion method
Cytotoxicity against human Kasumi-1 cells by trypan blue exclusion method
|
[PMID: 14987068] |
| KB | ED50 |
17 μg/mL
Compound: Bruceantine
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 7130986] |
| LNCaP | ED50 |
11 nM
Compound: 6
|
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| Lu1 | ED50 |
12 nM
Compound: 6
|
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| MCF7 | ED50 |
0.27 nM
Compound: 6
|
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay in presence of 43 uM (-)-hydnocarpin
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay in presence of 43 uM (-)-hydnocarpin
|
[PMID: 19026551] |
| MCF7 | ED50 |
2 nM
Compound: 6
|
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| NB-4 | IC50 |
<15 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human NB4 cells by trypan blue exclusion method
Cytotoxicity against human NB4 cells by trypan blue exclusion method
|
[PMID: 14987068] |
| NCI-H929 | IC50 |
115 nM
Compound: Bruceantin
|
Induction of apoptosis in human NCI-H929 cells after 24 hrs by DAPI staining
Induction of apoptosis in human NCI-H929 cells after 24 hrs by DAPI staining
|
[PMID: 14987068] |
| REH | IC50 |
20 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human REH cells by trypan blue exclusion method
Cytotoxicity against human REH cells by trypan blue exclusion method
|
[PMID: 14987068] |
| RPMI-8226 | IC50 |
12.8 nM
Compound: Bruceantin
|
Induction of apoptosis in human RPMI8226 cells after 24 hrs by DAPI staining
Induction of apoptosis in human RPMI8226 cells after 24 hrs by DAPI staining
|
[PMID: 14987068] |
| RS4-11 | IC50 |
<15 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human RS4:11 cells by trypan blue exclusion method
Cytotoxicity against human RS4:11 cells by trypan blue exclusion method
|
[PMID: 14987068] |
| SU-DHL-6 | IC50 |
<15 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human DHL6 cells by trypan blue exclusion method
Cytotoxicity against human DHL6 cells by trypan blue exclusion method
|
[PMID: 14987068] |
| U-266 | IC50 |
49 nM
Compound: Bruceantin
|
Induction of apoptosis in human U266 cells after 24 hrs by DAPI staining
Induction of apoptosis in human U266 cells after 24 hrs by DAPI staining
|
[PMID: 14987068] |
| U-937 | IC50 |
<15 ng/mL
Compound: Bruceantin
|
Cytotoxicity against human U937 cells by trypan blue exclusion method
Cytotoxicity against human U937 cells by trypan blue exclusion method
|
[PMID: 14987068] |
Bruceantin (2.5-40 ng/mL, 24 h) downregulates the expression of c-Myc in cell RPMI 8226, induces a decrease in mitochondrial membrane potential, leads to the release of cytochrome c, activates caspase-3/7, and induces apoptosis in cells RPMI 8226, U266 and H929 with IC50s of 13, 49 and 115 nM, respectively[1].
Bruceantin (0.1-1 μg/mL, 4-5 days) exhibits anti-amoebic activity, inhibits Entamoeba histolytica with an IC50 of 0.018 μg/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse RPMI 8226 xenograft models[1]
-
Dosage:1.25-12 mg/kg
-
Administration:ip, every 3 days for 40 days
-
Result:Inhibited tumor growth.
Chemical Information
-
No. CAS 41451-75-6
-
Appearance Solid
-
Peso molecular 548.58
-
Fòrmula C28H36O11
-
Color White to off-white
-
SMILES
O=C([C@@]1([C@H]([C@H](O)[C@]2([H])[C@]3(C4)C)O)[C@@]([C@H](C5=O)OC(/C=C(C)/C(C)C)=O)([H])[C@@]2([C@@](O5)([H])C[C@@]3([H])C(C)=C(O)C4=O)CO1)OC
-
Synonyms
(-)-Bruceantin; NCI165563; NSC165563
-
Structure Classification
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]2025 Dec 24:150:157740. PMID: 41477978 -
bioRxiv
Translation inhibition efficacy does not determine the Plasmodium berghei liver stage antiplasmodial efficacy of protein synthesis inhibitors. [Abstract]2023 Dec 7:2023.12.07.570699. PMID: 38106175
Solvente y solubilidad
DMSO : 100 mg/mL (182.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Cuendet M, et al. Multiple myeloma regression mediated by bruceantin. Clin Cancer Res. 2004 Feb 1;10(3):1170-9. [Content Brief]
[2]. Cuendet M, et al. Antitumor activity of bruceantin: an old drug with new promise. J Nat Prod. 2004 Feb;67(2):269-72. [Content Brief]
[3]. Gillin FD, et al., Bruceantin, a potent amoebicide from a plant, Brucea antidysenterica. Antimicrob Agents Chemother. 1982 Aug;22(2):342-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8229 mL | 9.1144 mL | 18.2289 mL | 45.5722 mL |
| 5 mM | 0.3646 mL | 1.8229 mL | 3.6458 mL | 9.1144 mL | |
| 10 mM | 0.1823 mL | 0.9114 mL | 1.8229 mL | 4.5572 mL | |
| 15 mM | 0.1215 mL | 0.6076 mL | 1.2153 mL | 3.0381 mL | |
| 20 mM | 0.0911 mL | 0.4557 mL | 0.9114 mL | 2.2786 mL | |
| 25 mM | 0.0729 mL | 0.3646 mL | 0.7292 mL | 1.8229 mL | |
| 30 mM | 0.0608 mL | 0.3038 mL | 0.6076 mL | 1.5191 mL | |
| 40 mM | 0.0456 mL | 0.2279 mL | 0.4557 mL | 1.1393 mL | |
| 50 mM | 0.0365 mL | 0.1823 mL | 0.3646 mL | 0.9114 mL | |
| 60 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.7595 mL | |
| 80 mM | 0.0228 mL | 0.1139 mL | 0.2279 mL | 0.5697 mL | |
| 100 mM | 0.0182 mL | 0.0911 mL | 0.1823 mL | 0.4557 mL |
Bruceantin Related Classifications
HY-N0840 Related Classifications
Powered by Bioz